Capital Flow Monitor · Sponsors · CIK 1797409
Cambrian BioPharma Inc
228 Park Avenue South, NEW YORK, NY, 10003 · (516) 962-3186
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$129.8M
Sold
$123.8M
% sold
95.4%
Investors
80
Min investment
$0
Exemption
506(c)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | D ·current | 506(c) | $129.8M | $123.8M | 95.4% | 80 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
James Peyer — Executive Officer / Director, New York, NY
1 other raise
- Rapalogix Health, Inc. $19.1M of $25.0M · 76.5%
-
Juliette Han — Executive Officer / Director, New York, NY
1 other raise
- Rapalogix Health, Inc. $19.1M of $25.0M · 76.5%
- Mark Nuttall — Executive Officer, New York, NY
- Ruth Thieroff-Ekerdt — Executive Officer, New York, NY
- William DeVaul — Executive Officer, New York, NY
- Christian Angermeyer — Director, Birkirkara, O1
-
Maryanna Saenko — Director, Los Altos, CA
3 other raises
- Future Ventures PNT 1, LLC $78.3M of $78.3M · 100.0%
- Gameto, Inc. $44.0M of $44.0M · 100.0%
- Future Ventures Commonwealth Fusion Fund II, LLC $19.6M of $19.6M · 100.0%
- Brenton L. Saunders — Director, Bridgewater, NJ
- Paul Farr — Director, Santa Monica, CA
- Martin Gunhaga — Director, Umea, V7
- Lorin Van Nuland — Director, Birkirkara, O1
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.